Ubs Group Ag Cin Cor Pharma, Inc. Transaction History

Ubs Group Ag

  • $400 Billion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 08, 2023
BUY
$10.75 - $29.84 $1.24 Million - $3.45 Million
115,690 Added 504.67%
138,614 $1.7 Million
Q3 2022

Nov 10, 2022
BUY
$19.9 - $38.94 $438,834 - $858,704
22,052 Added 2528.9%
22,924 $753,000
Q2 2022

Aug 10, 2022
SELL
$13.67 - $25.74 $17,538 - $33,024
-1,283 Reduced 59.54%
872 $16,000
Q1 2022

May 16, 2022
BUY
$14.13 - $28.49 $30,450 - $61,395
2,155 New
2,155 $38,000

Others Institutions Holding CINC

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About CinCor Pharma, Inc.

CINC Quotes by TradingView
  • Ticker CINC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,764,300
  • Description
  • CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial...
More about CINC
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email